The recent reports of hypertension as a comorbidity in COVID-19 patients (Fang et al., 2020) and specifically the use of ACE inhibitors as antihypertensives contributing to mortality encourages a hypothesis-free examination of the FDA adverse event reporting system (FAERS; see Materials and Methods). The gene discussed is ACE; the disease is COVID-19.